<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>5</patient-age><report-id>PHHY2010GR74124</report-id><gender>unknown</gender><reactions><reaction>Hypokalemia</reaction><reaction>Abdominal pain</reaction><reaction>Vomiting</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ICL670A </drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DIURENE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Thalassaemia</indication><indication>Iron overload</indication><indication>Hypercalciuria</indication></indications><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Greece</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053095_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133608</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHHY2010GR74124</safetyreportid>
		<primarysourcecountry>GR</primarysourcecountry>
		<occurcountry>GR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2010-11-03</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-11-28</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2010GR74124</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>H</reportergivename>
			<reporterfamilyname>Berdoussi</reporterfamilyname>
			<reporterorganization>AG Sophia Children's Hospital</reporterorganization>
			<reportercountry>GR</reportercountry>
			<qualification code="1">Physician</qualification>
			<sponsorstudynumb>CICL670A2411</sponsorstudynumb>
			<observestudytype>2</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>STK</patientinitial>
			<patientinvestigationnumb>0005</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>20050424</patientbirthdate>
			<patientweight>17</patientweight>
			<patientheight>110</patientheight>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypercalciuria</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Thalassaemia</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Hypokalemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypokalemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypokalaemia</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20101030</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20101105</reactionenddate>
				<reactionduration>7</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>471</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Abdominal pain</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Abdominal pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Abdominal pain</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20101105</reactionenddate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Vomiting</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Vomiting</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Vomiting</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20101030</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20101105</reactionenddate>
				<reactionduration>7</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>471</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Alanine aminotransferase increased</testname>
				<testresult>110</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Alanine aminotransferase increased</testname>
				<testresult>110</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101102</testdate>
				<testname>Alanine aminotransferase increased</testname>
				<testresult>442</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101102</testdate>
				<testname>Alanine aminotransferase increased</testname>
				<testresult>442</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Aspartate aminotransferase</testname>
				<testresult>26</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Aspartate aminotransferase</testname>
				<testresult>26</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood calcium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood chloride</testname>
				<testresult>105 mEq/L</testresult>
				<testunit>mg/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood chloride</testname>
				<testresult>105 mEq/L</testresult>
				<testunit>mg/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood phosphorus</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101102</testdate>
				<testname>Blood phosphorus</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood potassium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101102</testdate>
				<testname>Blood potassium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood sodium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood urea</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ICL670A </medicinalproduct>
				<obtaindrugcountry>GR</obtaindrugcountry>
				<drugauthorizationnumb>21-882</drugauthorizationnumb>
				<drugauthorizationcountry>GR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>625</drugstructuredosagenumb>
				<drugstructuredosageunit code="007"/>
				<drugdosagetext>625 mg/kg, daily</drugdosagetext>
				<drugdosageform normalized="dispersible tablet">Dispersible Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Thalassaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2009-07-17</drugstartdate>
				<drugstartperiod>471</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2010-10-30</drugenddate>
				<drugtreatmentduration>471</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>*CGP 72670*</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ICL670A </medicinalproduct>
				<obtaindrugcountry>GR</obtaindrugcountry>
				<drugauthorizationnumb>21-882</drugauthorizationnumb>
				<drugauthorizationcountry>GR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosageform normalized="dispersible tablet">Dispersible Tablet</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Iron overload</drugindication>
				<drugstartperiod>471</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>*CGP 72670*</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>DIURENE</medicinalproduct>
				<obtaindrugcountry>GR</obtaindrugcountry>
				<drugauthorizationcountry>GR</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugdosagetext>0.5 DF, daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypercalciuria</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-06-08</drugstartdate>
				<drugstartperiod>145</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2010-10-30</drugenddate>
				<drugtreatmentduration>145</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMILORIDE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical><Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">Initial </Semaphore>post marketing study report received from an investigator on 03 Nov 2010: This patient had a medical history of <Semaphore x="2609781" class="Disease or Finding" value="Thalassemia" score="1.00" ID="C35069">thalassemia</Semaphore>. The patient was on <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="560788" class="Medicine" value="Exjade" score="0.99" ID="276840">Exjade </Semaphore>(<Semaphore x="435329" class="Medicine" value="deferasirox" score="0.74" ID="276843">deferasirox</Semaphore>) for <Semaphore x="1607470" class="Procedure" value="Blood Transfusion" score="1.00" ID="C15192">transfusion </Semaphore><Semaphore x="2080459" class="Disease or Finding" value="Iron Overload" score="1.00" ID="C78393"><Semaphore x="744254" class="Medicine" value="Iron" score="0.74" ID="297813">iron </Semaphore>overload </Semaphore>from 17 Jul 2009 to 30 Oct 2010 at a dose of 625mg (37mg/kg daily). The patient <Semaphore x="2005619" class="Procedure" value="Have Pain" score="1.00" ID="C91126">had developed <Semaphore x="1405770" class="Disease or Finding" value="Abdominal Pain" score="1.00" ID="C26682">abdominal pain </Semaphore></Semaphore>and <Semaphore x="2693861" class="Disease or Finding" value="Vomiting" score="1.00" ID="C3442">vomiting</Semaphore>. The patient also concomitantly took Diuren for <Semaphore x="3015479" class="MedDRA LLT" value="Hypercalciuria" score="1.00" ID="10020590">hypercalciuria </Semaphore>from 08 Jun 2010 to 30 Oct 2010. <Semaphore x="560788" class="Medicine" value="Exjade" score="0.99" ID="276840">Exjade </Semaphore>and Diuren were discontinued on the same date. The patient was examined on 02 Nov 2010 and was found to be weak and with diffuse <Semaphore x="2707172" class="MedDRA LLT" value="Abdominal tenderness" score="1.00" ID="10000097">abdominal <Semaphore x="2605134" class="Disease or Finding" value="Tenderness" score="1.00" ID="C75540">tenderness </Semaphore></Semaphore>especially on right upper quadrant. On 02 Nov 2010, laboratory evaluation has found the patient to have <Semaphore x="2039588" class="Disease or Finding" value="Hypokalemia" score="1.00" ID="C37974">hypokalemia </Semaphore>and transaminasaemia. The <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">lab </Semaphore>data was <Semaphore x="1469106" class="Procedure" value="Alanine Aminotransferase Measurement" score="1.00" ID="C64433">ALT </Semaphore>of 442 U/L, <Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore>of 2mmol/L and <Semaphore x="2814412" class="MedDRA LLT" value="Blood phosphorus" score="1.00" ID="10005717">phosphorus </Semaphore>of 1.4 mg/dL. The patient was hospitalized for IV hydration. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>assessed that the event <Semaphore x="2039588" class="Disease or Finding" value="Hypokalemia" score="1.00" ID="C37974">hypokalemia </Semaphore>can also be caused by Diuren. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event was reported to be improving by the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician</Semaphore>. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>assessed the causality for all events to be suspected.Follow up information received from an investigator on 15 Nov 2010: The patient had remained in the hospital. The patient was still taking IV <Semaphore x="2035359" class="Procedure" value="Hydration Therapy" score="1.00" ID="C66896">hydration <Semaphore x="3266267" class="MedDRA LLT" value="Supplementation therapy" score="1.00" ID="10066215">therapy </Semaphore></Semaphore>
    <Semaphore x="3266267" class="MedDRA LLT" value="Supplementation therapy" score="1.00" ID="10066215">and electrolyte <Semaphore x="2326755" class="Procedure" value="Nutritional Supplementation" score="1.00" ID="C15425">supplementation</Semaphore></Semaphore>. The patient had recovered <Semaphore x="2529816" class="Disease or Finding" value="Slow Growing Mass" score="1.00" ID="C41458">slowly </Semaphore>and after three days her <Semaphore x="3057951" class="MedDRA LLT" value="Laboratory test" score="1.00" ID="10059938">laboratory tests </Semaphore>were SGPT=110U/L(high) and P=2.0mg/dl(low),. On 05 Nov 2010, the patient had completely recovered. <Semaphore x="560788" class="Medicine" value="Exjade" score="0.99" ID="276840">Exjade </Semaphore>may have caused for renal dysfunction. All the events reported were suspected to <Semaphore x="560788" class="Medicine" value="Exjade" score="0.99" ID="276840">Exjade </Semaphore>and there was a possibility that Diuren also contributed to the events. No more information was available.Follow up report received from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 22 Nov 2010: The patient (patient ID: 0005 and centre ID: 702) received <Semaphore x="560788" class="Medicine" value="Exjade" score="0.99" ID="276840">Exjade </Semaphore>for <Semaphore x="1607470" class="Procedure" value="Blood Transfusion" score="1.00" ID="C15192">transfusion </Semaphore><Semaphore x="2080459" class="Disease or Finding" value="Iron Overload" score="1.00" ID="C78393"><Semaphore x="744254" class="Medicine" value="Iron" score="0.74" ID="297813">iron </Semaphore>overload </Semaphore><Semaphore x="2502875" class="Disease or Finding" value="Second-Degree Burn" score="1.00" ID="C76131">secondary </Semaphore>to <Semaphore x="2609781" class="Disease or Finding" value="Thalassemia" score="1.00" ID="C35069">thalassemia</Semaphore>. The patient had taken an exit ticket from the hospital at the time of report. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapies </Semaphore>of <Semaphore x="560788" class="Medicine" value="Exjade" score="0.99" ID="276840">Exjade </Semaphore>(<Semaphore x="435329" class="Medicine" value="deferasirox" score="0.74" ID="276843">deferasirox</Semaphore>) and Diuren had been stopped since 30 Oct 2010. The patient has been <Semaphore x="2588752" class="Procedure" value="Study of High Risk Factors" score="1.00" ID="C62697">withdrawn </Semaphore>from study. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of <Semaphore x="2693861" class="Disease or Finding" value="Vomiting" score="1.00" ID="C3442">vomiting</Semaphore><Semaphore x="1405770" class="Disease or Finding" value="Abdominal Pain" score="1.00" ID="C26682">, <Semaphore x="1405770" class="Disease or Finding" value="Abdominal Pain" score="1.00" ID="C26682">abdominal pain </Semaphore></Semaphore>and <Semaphore x="2039588" class="Disease or Finding" value="Hypokalemia" score="1.00" ID="C37974">hypokalemia </Semaphore>was reported as completely recovered on 05 Nov 2010.Follow up report received on 27 Nov 2012: During <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization </Semaphore>the patient (patient number: 0005 and center number: 702) was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>with renal dysfunction, weak, diffuse <Semaphore x="2707172" class="MedDRA LLT" value="Abdominal tenderness" score="1.00" ID="10000097">abdominal <Semaphore x="2605134" class="Disease or Finding" value="Tenderness" score="1.00" ID="C75540">tenderness </Semaphore></Semaphore>especially on right upper quadrant, transaminasemia events and these events were assessed as non serious. The event experienced <Semaphore x="2039588" class="Disease or Finding" value="Hypokalemia" score="1.00" ID="C37974">hypokalemia </Semaphore>was assessed as non serious and consequence of severe <Semaphore x="2693861" class="Disease or Finding" value="Vomiting" score="1.00" ID="C3442">vomiting</Semaphore>.Follow up report received on 28 Nov 2012: The investigator reported that renal dysfunction, weak, diffuse <Semaphore x="2707172" class="MedDRA LLT" value="Abdominal tenderness" score="1.00" ID="10000097">abdominal <Semaphore x="2605134" class="Disease or Finding" value="Tenderness" score="1.00" ID="C75540">tenderness </Semaphore></Semaphore>especially on right upper quadrant and transaminasemia were not serious <Semaphore x="2724216" class="MedDRA LLT" value="Adverse event" score="1.00" ID="10060933">adverse events </Semaphore>but the finding during <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>. Added patient details and causality was updated as not suspected to the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="560788" class="Medicine" value="Exjade" score="0.99" ID="276840">Exjade</Semaphore>.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>